Abiraterone active after diethylstilboestrol treatment

Access through your institution Buy or subscribe Men with castration-resistant prostate cancer who have previously received diethylstilboestrol treatment can still benefit from abiraterone,

according to the results of a new study. In a cohort of 247 patients who received abiraterone, 114 (41.6%) men were found to have previously received diethylstilboestrol. The proportion of

patients who experienced ≥50% PSA decline were similar for men who had and had not received diethylstilboestrol, in both the prechemotherapy (74.1% versus 85.4%) and postchemotherapy (28.4%

versus 35.4%) settings. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print

issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support ORIGINAL RESEARCH

PAPER * Omlin, A. _ et al_. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. _Br. J. Cancer_

doi:10.1038/bjc.2013.446 Download references RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Abiraterone active after diethylstilboestrol treatment. _Nat

Rev Urol_ 10, 556 (2013). https://doi.org/10.1038/nrurol.2013.192 Download citation * Published: 27 August 2013 * Issue Date: October 2013 * DOI: https://doi.org/10.1038/nrurol.2013.192

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to

clipboard Provided by the Springer Nature SharedIt content-sharing initiative